<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27809891</article-id><article-id pub-id-type="pmc">5094139</article-id><article-id pub-id-type="publisher-id">1149</article-id><article-id pub-id-type="doi">10.1186/s13075-016-1149-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Pelletier</surname><given-names>Jean-Pierre</given-names></name><address><phone>514-890-8000x26659</phone><email>dr@jppelletier.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Raynauld</surname><given-names>Jean-Pierre</given-names></name><address><email>jp.raynauld@videotron.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Beaulieu</surname><given-names>Andr&#x000e9; D.</given-names></name><address><email>ab5@videotron.ca</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bessette</surname><given-names>Louis</given-names></name><address><email>louis.bessette@crchul.ulaval.ca</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Morin</surname><given-names>Fr&#x000e9;d&#x000e9;ric</given-names></name><address><email>crms@cgocable.ca</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>de Brum-Fernandes</surname><given-names>Artur J.</given-names></name><address><email>artur.fernandes@usherbrooke.ca</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Delorme</surname><given-names>Philippe</given-names></name><address><email>pdelorme@arthrolab.com</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Dorais</surname><given-names>Marc</given-names></name><address><email>marc.dorais.statsciences@gmail.com</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Paiement</surname><given-names>Patrice</given-names></name><address><email>ppaiement@arthrolab.com</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Abram</surname><given-names>Fran&#x000e7;ois</given-names></name><address><email>fabram@arthrovision.biz</email></address><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Martel-Pelletier</surname><given-names>Johanne</given-names></name><address><email>jm@martelpelletier.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), 900 Saint-Denis, Suite R11.412, Montreal, Quebec H2X 0A9 Canada </aff><aff id="Aff2"><label>2</label>Institut de rhumatologie de Montr&#x000e9;al, Montreal, Quebec Canada </aff><aff id="Aff3"><label>3</label>Centre de rhumatologie St-Louis, Sainte-Foy, Quebec Canada </aff><aff id="Aff4"><label>4</label>Groupe de recherche en Rhumatologie et Maladies Osseuses Inc., Sainte-Foy, Quebec Canada </aff><aff id="Aff5"><label>5</label>Centre de recherche musculo-squelettique, Trois-Rivi&#x000e8;res, Quebec Canada </aff><aff id="Aff6"><label>6</label>Service de rhumatologie, Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec Canada </aff><aff id="Aff7"><label>7</label>ArthroLab Inc., Montreal, Quebec Canada </aff><aff id="Aff8"><label>8</label>StatSciences Inc., Notre-Dame de l&#x02019;&#x000ce;le-Perrot, Quebec Canada </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>18</volume><elocation-id>256</elocation-id><history><date date-type="received"><day>13</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>6</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>In osteoarthritis (OA) treatment, although chondroitin sulfate (CS) was found in a number of studies using radiography to have a structure-modifying effect, to date CS use is still under debate. A clinical study using quantitative magnetic resonance imaging (qMRI) is therefore of the utmost importance. Here we report data from a 24-month, randomised, double-blind, double-dummy, controlled, comparative exploratory study of knee OA. The primary endpoint was to determine the effect of CS 1200&#x000a0;mg/day versus celecoxib 200&#x000a0;mg/day on cartilage volume loss (CVL) in the lateral compartment over time as measured by qMRI. Secondary endpoints included assessment of the OA structural changes and signs and symptoms of OA.</p></sec><sec><title>Methods</title><p>qMRI was performed at baseline and at 12 and 24&#x000a0;months. CVL, bone marrow lesion size, and synovial thickness were evaluated using qMRI. The primary statistical analysis was carried out on the modified intention-to-treat (mITT) population (<italic>n</italic>&#x02009;=&#x02009;138) using chi-squared, Fisher&#x02019;s exact, Wilcoxon Mann&#x02013;Whitney, and Student&#x02019;s <italic>t</italic> tests and analysis of covariance. Analyses were also conducted on the according-to-protocol (ATP; <italic>n</italic>&#x02009;=&#x02009;120) population.</p></sec><sec><title>Results</title><p>In the adjusted mITT analysis, compared with celecoxib treatment, patients treated with CS had a significant reduced CVL at 24&#x000a0;months in the medial compartment (celecoxib &#x02013;8.1&#x000a0;%&#x02009;&#x000b1;&#x02009;4.2, CS &#x02013;6.3&#x000a0;%&#x02009;&#x000b1;&#x02009;3.2; <italic>p</italic>&#x02009;=&#x02009;0.018) and medial condyle (&#x02013;7.7&#x000a0;%&#x02009;&#x000b1;&#x02009;4.7, &#x02013;5.5&#x000a0;%&#x02009;&#x000b1;&#x02009;3.9; <italic>p</italic>&#x02009;=&#x02009;0.008); no significant effect was seen in the lateral compartment. In the ATP population, CS reduced CVL in the medial compartment at 12&#x000a0;months (celecoxib &#x02013;5.6&#x000a0;%&#x02009;&#x000b1;&#x02009;3.0, CS &#x02013;4.5&#x000a0;%&#x02009;&#x000b1;&#x02009;2.6; <italic>p</italic>&#x02009;=&#x02009;0.049) and 24&#x000a0;months (celecoxib &#x02013;8.4&#x000a0;%&#x02009;&#x000b1;&#x02009;4.2, CS &#x02013;6.6&#x000a0;%&#x02009;&#x000b1;&#x02009;3.3; <italic>p</italic>&#x02009;=&#x02009;0.021), and in the medial condyle at 24&#x000a0;months (celocoxib &#x02013;8.1&#x000a0;%&#x02009;&#x000b1;&#x02009;4.7, CS &#x02013;5.7&#x000a0;%&#x02009;&#x000b1;&#x02009;4.0; <italic>p</italic>&#x02009;=&#x02009;0.010). A trend towards a statistically reduced synovial thickness (celecoxib +17.96&#x02009;&#x000b1;&#x02009;33.73&#x000a0;mm, CS &#x02013;0.66&#x02009;&#x000b1;&#x02009;22.72&#x000a0;mm; <italic>p</italic>&#x02009;=&#x02009;0.076) in the medial suprapatellar bursa was observed in CS patients. Both groups experienced a marked reduction in the incidence of patients with joint swelling/effusion and in symptoms over time. Data showed similar good safety profiles including cardiovascular adverse events for both drugs.</p></sec><sec><title>Conclusion</title><p>This study demonstrated, for the first time in a 2-year randomised controlled trial using qMRI, the superiority of CS over celecoxib at reducing CVL in knee OA patients.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=NCT01354145">NCT01354145</ext-link>. Registered 13 May 2011.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13075-016-1149-0) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chondroitin sulfate</kwd><kwd>Symptomatic slow-acting drug in osteoarthritis</kwd><kwd>Osteoarthritis</kwd><kwd>Knee</kwd><kwd>Celecoxib</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Knee osteoarthritis (OA) is one of the most common musculoskeletal disorders, which causes joint pain, stiffness, and loss of function [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Current treatment recommendations include a combination of non-pharmacological (e.g. education, exercise, weight loss) and pharmacological (e.g. acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs)) treatments, and some also suggest the use of symptomatic slow-acting drugs for osteoarthritis (SYSADOA) [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>], which include chondroitin sulfate (CS) and glucosamine. However, the use of the latest line of treatment has not reached a general consensus among different guidelines [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], due in part to the unavailability of prescription quality SYSADOAs indicated for use in OA that have been evaluated by the US Food and Drug Administration [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>The goals of OA therapy are to decrease pain and maintain or improve joint function. Existing pharmacologic therapies for OA, namely NSAIDs and analgesics, help to reduce symptoms, but are only moderately effective and expose patients to potential significant toxicity (cardiovascular, hepatic, renal, and other adverse events (AEs)) and problems resulting from interactions with other medications. A recent systematic literature review suggests that paracetamol, especially at the upper end of standard analgesic doses, can also induce gastrointestinal events (i.e. gastroduodenal ulcers and complications such as upper gastrointestinal haemorrhages) and renal events (decrease in glomerular filtration rate) [<xref ref-type="bibr" rid="CR8">8</xref>]. For this reason, attention has recently been focused on the investigation and development of new types of drugs and treatments that can improve the clinical symptoms of OA and show better safety profiles, such as symptomatic SYSADOAs. SYSADOAs such as CS are characterised by a slow onset of action and a global efficacy at reducing OA symptoms similar to that of NSAIDs, and also possess a carry-over effect. Furthermore, 6-month randomised controlled trials (RCTs) using similar grade preparations have shown that CS 1200&#x000a0;mg/day plus glucosamine 1500&#x000a0;mg/day can provide significant pain relief over placebo [<xref ref-type="bibr" rid="CR9">9</xref>] and comparable pain relief with celecoxib [<xref ref-type="bibr" rid="CR10">10</xref>] in a subgroup of patients with moderate-to-severe knee pain.</p><p>CS is a natural product extracted from animal cartilage (e.g. bovine trachea). A recent Cochrane review concluded that CS, alone or in combination with glucosamine, has a beneficial effect on pain and joint space narrowing (JSN) in patients with knee OA [<xref ref-type="bibr" rid="CR11">11</xref>]. Of note, different sources of CS with variable composition and purity have been used in these studies, which may explain some heterogeneity of results [<xref ref-type="bibr" rid="CR12">12</xref>]. RCTs using pharmaceutical-grade preparations of CS have shown that at 800&#x000a0;mg/day the treatment significantly reduced JSN as assessed using X-ray imaging [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>], and decreased cartilage volume loss as evaluated by magnetic resonance imaging (MRI) in a pilot study [<xref ref-type="bibr" rid="CR16">16</xref>]. In OA joint tissues, CS has been shown to modify the chondrocyte death process, to improve the anabolic/catabolic balance of the extracellular cartilage matrix, to reduce some pro-inflammatory and catabolic factors, and to reduce the resorptive properties of subchondral bone osteoblasts [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. These findings support the mode of action of CS at reducing OA structural change progression.</p><p>The aim of the current study was to ascertain whether CS at 1200&#x000a0;mg/day, the maximum and most commonly used therapeutic dosage of CS alone or in combination with other drugs/agents such as glucosamine, over a period of 24 months would reduce cartilage volume loss, as assessed by MRI. Celecoxib was chosen as the comparator for many reasons. First, it was shown in an RCT using MRI that celecoxib and placebo have a non-different effect on the progression of cartilage volume loss in knee OA patients [<xref ref-type="bibr" rid="CR22">22</xref>]. Moreover, celecoxib has an established efficacy in knee OA treatment and widespread use [<xref ref-type="bibr" rid="CR23">23</xref>]. It is preferred over other NSAIDs due to its lower incidence of gastrointestinal side effects.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>This 24-month randomised, double-blind, double-dummy controlled study (ClinicalTrials.gov NCT01354145) of patients with symptomatic knee OA and clinical synovitis aimed to explore the effect of CS and celecoxib on knee OA cartilage volume loss. The study was performed in Quebec, Canada. Patients were recruited by physicians in four private clinics and one outpatient clinic (Service de rhumatologie, Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada).</p></sec><sec id="Sec4"><title>Patients</title><p>The study enrolled ambulatory men and women aged 40&#x000a0;years or older with primary symptomatic knee OA whose condition justified symptomatic treatment, as described previously [<xref ref-type="bibr" rid="CR16">16</xref>]. They were diagnosed according to the clinical and radiological criteria of the American College of Rheumatology (ACR) [<xref ref-type="bibr" rid="CR24">24</xref>], with clinical signs of synovitis (warmth, swelling, or effusion), a disease severity grade of 2&#x02013;3 based on Kellgren&#x02013;Lawrence radiographic scoring [<xref ref-type="bibr" rid="CR25">25</xref>], a minimal medial joint space width of 2&#x000a0;mm on standing knee X-ray scan, and a visual analogue scale (VAS) pain index of at least 40&#x000a0;mm while walking. The X-ray inclusion criteria were selected not only to comply with ACR recommendations but also to avoid selection of patients with secondary OA and/or with too severe disease such as knee varus/valgus malalignment. Concomitant femoropatellar OA was not quantified by X-ray imaging. Participants were required to have no significant laboratory abnormalities. If both knees were affected by OA, the target knee with the most pronounced symptoms was selected if within the inclusion criteria. Full inclusion and exclusion criteria are presented in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1.</p></sec><sec id="Sec5"><title>Treatments</title><p>Patients were assigned sequentially in a 1:1 ratio according to a predefined randomisation scheme using a mathematical algorithm and a randomisation list (Ropack Pharmaceutical Packaging, Montreal, QC, Canada). The list contained assignment of sequential numbers to one of the two treatment groups, pharmaceutical-grade CS (Bioib&#x000e9;rica S.A., Barcelona, Spain) 1200&#x000a0;mg (three 400&#x000a0;mg capsules in the morning) or celecoxib (Pfizer Canada, Saint-Laurent, QC, Canada) 200&#x000a0;mg (one 200&#x000a0;mg capsule&#x02009;+&#x02009;two placebo capsules in the morning) for 24&#x000a0;months. All products were over-encapsulated to have the same appearance, size, and colour. The patients, site personnel, and sponsor were blinded to treatment.</p><p>Patients were not permitted to take other NSAIDs during the study (or during the week before randomisation), but could take acetaminophen (up to 3&#x000a0;g/day) with consumption interrupted 48&#x000a0;hours preceding evaluations.</p><p>The prior and concomitant treatment, blinding, treatment compliance, and study schedule are described in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Methods.</p></sec><sec id="Sec6"><title>Outcomes</title><p>The primary endpoint was percentage of cartilage volume loss over time in the lateral compartment (condyle and tibial plateau) of the target knee from baseline to 24&#x000a0;months. The decision for selecting this criterion was based on the findings of the pilot study [<xref ref-type="bibr" rid="CR16">16</xref>] and those of other similar RCTs [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The secondary endpoints included changes in percentage of cartilage volume loss in the medial compartment, synovitis severity (thickness of the synovial membrane), bone marrow lesion (BML) grade, and synovial fluid volume. The outcomes also included assessment on the VAS of knee pain, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, quality of life (QoL) Short Form-36 General Health (SF-36) scores, clinical evaluation (swelling, visual examination; effusion, bulge sign), analgesic consumption, and AEs, which were recorded during physical examinations at the baseline visit and follow-up visits at months 3, 6, 9, 12, 18, and 24. Safety outcomes included discontinuation of study treatment due to AEs, and changes in various laboratory measures and vital signs.</p><sec id="Sec7"><title>Knee MRI acquisitions</title><p>MRI was performed at baseline and at 12 and 24&#x000a0;months on 1.5&#x000a0;T scanners (Siemens, Erlangen, Germany; General Electric, Milwaukee, WI, USA) using a standard knee coil. The sequence acquisitions were as described previously for the cartilage [<xref ref-type="bibr" rid="CR28">28</xref>] and synovial membrane [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>The cartilage volume was measured by two experienced readers trained by musculoskeletal radiologists using the computer program Cartiscope&#x02122; (ArthroLab, Montreal, QC, Canada) as described previously [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The readers were blinded to treatment and to MRI examination time points except for the baseline. The change in knee cartilage volume was obtained by subtracting the follow-up volume from the initial (baseline) volume. The reproducibility of the method has been demonstrated previously to be excellent: root mean square (RMS) coefficient of variation percentage (CV%) of 2.2&#x000a0;% for the global cartilage volume, 1.6&#x000a0;% for the medial compartment, and 2.6&#x000a0;% for the lateral compartment [<xref ref-type="bibr" rid="CR30">30</xref>] and inter-reader and intra-reader intra-class correlation (ICC) of 0.94&#x02013;0.99 [<xref ref-type="bibr" rid="CR32">32</xref>]. In addition, the reproducibility of the reading is evaluated periodically using standard operating procedures (SOP; ArthroLab). The data show consistency of the method over time.</p><p>The extent of synovitis was assessed by measuring synovial thickness (mm) in four regions of interest (ROIs): the medial and lateral articular recess and the medial and lateral outer wall of the suprapatellar bursa [<xref ref-type="bibr" rid="CR29">29</xref>]. The inter-reader and intra-reader correlation was excellent with ICC of 0.82&#x02013;0.91 [<xref ref-type="bibr" rid="CR29">29</xref>] and consistency of the method over time (SOP; ArthroLab). Of note, the measurement of the synovial membrane thickness according to this method relies on the presence of synovial fluid to localise the membrane in the different ROIs. An absence of synovial fluid, especially in the area of the medial suprapatellar bursa, thus accounts for missing values.</p><p>The synovial fluid was determined using a fully automated system as described previously [<xref ref-type="bibr" rid="CR33">33</xref>]. Validation experiments revealed excellent coefficients of variation with a calibrated cylinder (1.4&#x000a0;%), sphere phantoms (0.8&#x000a0;%), manual quantification (<italic>r</italic>&#x02009;=&#x02009;0.98, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001), and comparison with direct aspiration (<italic>r</italic>&#x02009;=&#x02009;0.88, <italic>p</italic>&#x02009;=&#x02009;0.0008) [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>BML were assessed in the same MRI sequences used for the cartilage [<xref ref-type="bibr" rid="CR34">34</xref>]. The extent of the BML was evaluated in the global knee and each of the subregions using the following scale: 0, absence; 1, &#x0003c;25&#x000a0;%; 2, 25&#x02013;50&#x000a0;%, 3, &#x0003e;50&#x000a0;% of the surface of the respective region regardless of the presence of additional smaller lesions. Reliability of the scoring system for BML changes was found to be excellent with ICC ranging from 0.88 to 0.93 [<xref ref-type="bibr" rid="CR34">34</xref>] and consistency of the method over time (SOP; ArthroLab).</p></sec></sec><sec id="Sec8"><title>Statistical analysis</title><p>The study populations were carefully defined in the statistical analysis plan (SAP). The safety population included all randomised patients who received at least one dose of study treatment (<italic>n</italic>&#x02009;=&#x02009;194 at baseline). The modified intention-to-treat (mITT) population comprised all randomised patients who received at least one dose of study medication and for whom at least one post-baseline efficacy MRI measurement was available. The according-to-protocol (ATP) population included patients who fully complied with the study&#x02019;s 24-month protocol and for whom all MRI evaluations were available. Data were entered into a computerised database using a blinded double-entry procedure, after which descriptive statistics for patient characteristics were tabulated. Before locking the database, the following actions were performed under conditions blinded for the type of intervention: the database was cleaned, all queries were resolved, a review meeting regarding blinded data was conducted, protocol deviations were identified, the SAP was developed, and signed approval was obtained. Following the final database lock, the statistical analysis was performed by an independent expert biostatistics firm (Inferential, Paris, France).</p><p>Descriptive variables at baseline are presented as number (percentage) or mean&#x02009;&#x000b1;&#x02009;standard deviation (SD). Differences between the two treatment groups were assessed using a Kruskal&#x02013;Wallis test or Student&#x02019;s <italic>t</italic> test for quantitative variables, and a chi-squared test or Fisher&#x02019;s exact test for categorical variables. Analgesic consumption was tallied and compared between the two groups. The primary efficacy outcome measure for structure modification was percentage cartilage volume loss in the lateral compartment of the target knee after 24&#x000a0;months of enrolment for the mITT population who had at least one post-baseline MRI measurement while using, as specified in the SAP, the imputation method of the last observation carried forward (mITT-LOCF). Because of the difference at baseline in body mass index (BMI) values between the two treatment groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), an analysis of covariance (ANCOVA) including BMI as a covariate was performed on the mITT-LOCF population. In order to provide an additional measure of treatment efficacy, the ATP population (i.e. patients who completed the study according to the 24-month protocol) was also assessed using the ANCOVA method. Additionally, the data from the mITT and ATP populations were also analysed using a generalised linear mixed-model analysis. Secondary efficacy analyses of structural changes were done using the same methodology. Comparison of symptom changes using the WOMAC questionnaire, VAS pain, QoL SF-36, knee swelling and effusion, and safety were assessed on all available data as specified in the SAP.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Randomised patient characteristics at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Chondroitin sulfate<break/>(<italic>n</italic>&#x02009;=&#x02009;97)</th><th>Celecoxib<break/>(<italic>n</italic>&#x02009;=&#x02009;97)</th></tr></thead><tbody><tr><td>Female</td><td>53 (54.6)</td><td>61 (62.9)</td></tr><tr><td>Age (years)</td><td>61.4&#x02009;&#x000b1;&#x02009;9.3</td><td>61.3&#x02009;&#x000b1;&#x02009;8.5</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>30.1&#x02009;&#x000b1;&#x02009;5.8</td><td>32.3&#x02009;&#x000b1;&#x02009;5.8</td></tr><tr><td>At least one previous medical condition</td><td>86 (88.7)</td><td>86 (88.7)</td></tr><tr><td>At least one active medical condition</td><td>96 (99.0)</td><td>97 (100.0)</td></tr><tr><td colspan="3">Cartilage volume (mm<sup>3</sup>)</td></tr><tr><td>&#x02003;Lateral compartment</td><td>4613&#x02009;&#x000b1;&#x02009;1755</td><td>4405&#x02009;&#x000b1;&#x02009;1157</td></tr><tr><td>&#x02003;&#x02003;Condyle</td><td>2621&#x02009;&#x000b1;&#x02009;1073</td><td>2476&#x02009;&#x000b1;&#x02009;716</td></tr><tr><td>&#x02003;&#x02003;Plateau</td><td>1993&#x02009;&#x000b1;&#x02009;799</td><td>1930&#x02009;&#x000b1;&#x02009;540</td></tr><tr><td>&#x02003;Medial compartment</td><td>4515&#x02009;&#x000b1;&#x02009;1537</td><td>4255&#x02009;&#x000b1;&#x02009;1217</td></tr><tr><td>&#x02003;&#x02003;Condyle</td><td>2807&#x02009;&#x000b1;&#x02009;971</td><td>2646&#x02009;&#x000b1;&#x02009;779</td></tr><tr><td>&#x02003;&#x02003;Plateau</td><td>1708&#x02009;&#x000b1;&#x02009;623</td><td>1609&#x02009;&#x000b1;&#x02009;489</td></tr><tr><td>Synovial membrane thickness (mm)</td><td>1.0&#x02009;&#x000b1;&#x02009;0.2</td><td>1.0&#x02009;&#x000b1;&#x02009;0.2</td></tr><tr><td>BML score (global knee)<sup>a</sup>
</td><td>2.6&#x02009;&#x000b1;&#x02009;3.0</td><td>2.7&#x02009;&#x000b1;&#x02009;2.5</td></tr><tr><td>Synovial fluid volume (ml)</td><td>13.8&#x02009;&#x000b1;&#x02009;14.6</td><td>10.8&#x02009;&#x000b1;&#x02009;10.9</td></tr><tr><td colspan="3">Joint swelling and effusion</td></tr><tr><td>&#x02003;&#x02003;Swelling</td><td>76 (78.4)</td><td>78 (80.4)</td></tr><tr><td>&#x02003;&#x02003;Effusion</td><td>76 (78.4)</td><td>71 (73.2)</td></tr><tr><td>&#x02003;&#x02003;Both</td><td>59 (60.8)</td><td>55 (56.7)</td></tr><tr><td>Pain VAS (mm)<sup>a</sup>
</td><td>62.42&#x02009;&#x000b1;&#x02009;15.51</td><td>59.26&#x02009;&#x000b1;&#x02009;18.10</td></tr><tr><td colspan="3">WOMAC<sup>a</sup>
</td></tr><tr><td>&#x02003;&#x02003;Total score (0&#x02013;240)</td><td>124.9&#x02009;&#x000b1;&#x02009;38.1</td><td>126.7&#x02009;&#x000b1;&#x02009;43.9</td></tr><tr><td>&#x02003;&#x02003;Pain score (0&#x02013;50)</td><td>25.6&#x02009;&#x000b1;&#x02009;8.1</td><td>25.5&#x02009;&#x000b1;&#x02009;9.0</td></tr><tr><td>&#x02003;&#x02003;Stiffness score (0&#x02013;20)</td><td>10.8&#x02009;&#x000b1;&#x02009;3.7</td><td>11.7&#x02009;&#x000b1;&#x02009;4.3</td></tr><tr><td>&#x02003;&#x02003;Physical function score (0&#x02013;170)</td><td>88.5&#x02009;&#x000b1;&#x02009;28.7</td><td>89.5&#x02009;&#x000b1;&#x02009;32.5</td></tr><tr><td colspan="3">Quality of life (SF-36)<sup>a</sup>
</td></tr><tr><td>&#x02003;&#x02003;Physical component summary</td><td>35.4&#x02009;&#x000b1;&#x02009;7.8</td><td>35.7&#x02009;&#x000b1;&#x02009;8.1</td></tr><tr><td>&#x02003;&#x02003;Mental component summary</td><td>51.7&#x02009;&#x000b1;&#x02009;9.5</td><td>52.7&#x02009;&#x000b1;&#x02009;11.0</td></tr></tbody></table><table-wrap-foot><p>Data shown as number of patients (%) or mean&#x02009;&#x000b1;&#x02009;standard deviation</p><p>
<sup>a</sup>Data were not available for two patients in the chondroitin sulfate group</p><p>
<italic>BML</italic> bone marrow lesion, <italic>SF-36</italic> Short Form-36, <italic>VAS</italic> visual analogue scale, <italic>WOMAC</italic> Western Ontario and McMaster Universities Osteoarthritis Index</p></table-wrap-foot></table-wrap>
</p><p>No sample size estimation was carried out because this was an exploratory study. Statistical tests were two-sided and significance reached at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. No statistical adjustments were made for multiple comparisons while analysing secondary outcomes. Statistical analyses were performed using SAS&#x000ae; software version 9.3 (SAS Institute, Cary, NC, USA).</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Patients</title><p>The study was conducted from 21 June 2011 to 10 September 2014. A total of 194 patients were randomised to CS or celecoxib. The study populations used for analyses are as described in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Patient disposition. *Primary reasons for discontinuation. <sup>&#x02020;</sup>mITT includes ATP patients plus those with MRI at 12&#x000a0;months but with MRI missing at final visit. <italic>ATP</italic> according-to-protocol, <italic>mITT</italic> modified intention-to-treat, <italic>MRI</italic> magnetic resonance imaging</p></caption><graphic xlink:href="13075_2016_1149_Fig1_HTML" id="MO1"/></fig>
</p><p>No differences were found in the baseline characteristics of the patient populations (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) with the exception of BMI; although values for both groups were in the obesity category (&#x02265;30&#x000a0;kg/m<sup>2</sup>), a higher value was found in the celecoxib group.</p><p>No significant difference between the treatment groups was found for previous or concomitant medications (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p></sec><sec id="Sec11"><title>Efficacy</title><sec id="Sec12"><title>Cartilage volume</title><p>In the adjusted mITT-LOCF analysis (<italic>n</italic>&#x02009;=&#x02009;138), the percentage cartilage volume loss in the lateral compartment (primary endpoint) was not different in the CS (<italic>n</italic>&#x02009;=&#x02009;69) and celecoxib (<italic>n</italic>&#x02009;=&#x02009;69) groups at 24&#x000a0;months (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In the medial compartment and medial condyle, the cartilage volume loss was significantly less in the CS group at 24&#x000a0;months (<italic>p</italic>&#x02009;=&#x02009;0.018 and <italic>p</italic>&#x02009;=&#x02009;0.008, respectively) compared with celecoxib. The results from the generalised linear mixed-model analysis at 24&#x000a0;months showed <italic>p</italic>&#x02009;=&#x02009;0.038 for the medial compartment and <italic>p</italic>&#x02009;=&#x02009;0.015 for the medial condyle. However, the results of the adjusted analysis for the ATP population (<italic>n</italic>&#x02009;=&#x02009;120; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) showed a significant reduction in cartilage volume loss in CS-treated patients at 12&#x000a0;months for the medial compartment (<italic>p</italic>&#x02009;=&#x02009;0.049) and at 24&#x000a0;months for the medial compartment and medial condyle (<italic>p</italic>&#x02009;=&#x02009;0.021 and <italic>p</italic>&#x02009;=&#x02009;0.010, respectively). The results from the generalised linear mixed-model analysis showed <italic>p</italic>&#x02009;=&#x02009;0.043 and <italic>p</italic>&#x02009;=&#x02009;0.035 for the medial compartment at 12&#x000a0;months and 24&#x000a0;months, respectively, and <italic>p</italic>&#x02009;=&#x02009;0.015 for the medial condyle at 24&#x000a0;months.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Changes in MRI parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">mITT-LOCF population</th><th colspan="3">24&#x000a0;months</th><th/><th/><th/></tr><tr><th>Chondroitin sulfate</th><th>Celecoxib</th><th rowspan="2">
<italic>p</italic> value<sup>a</sup>
</th><th/><th/><th/></tr><tr><th>(<italic>n</italic>&#x02009;=&#x02009;69)</th><th>(<italic>n</italic>&#x02009;=&#x02009;69)</th><th/><th/><th/></tr></thead><tbody><tr><td colspan="7">Cartilage volume loss (%)</td></tr><tr><td>Lateral compartment</td><td>&#x02013;4.1&#x02009;&#x000b1;&#x02009;3.1</td><td>&#x02013;4.4&#x02009;&#x000b1;&#x02009;3.0</td><td>0.814</td><td/><td/><td/></tr><tr><td>&#x02003;Condyle</td><td>&#x02013;3.0&#x02009;&#x000b1;&#x02009;3.1</td><td>&#x02013;4.1&#x02009;&#x000b1;&#x02009;3.7</td><td>0.144</td><td/><td/><td/></tr><tr><td>&#x02003;Plateau</td><td>&#x02013;5.8&#x02009;&#x000b1;&#x02009;4.7</td><td>&#x02013;4.8&#x02009;&#x000b1;&#x02009;3.5</td><td>0.182</td><td/><td/><td/></tr><tr><td>Medial compartment</td><td>&#x02013;6.3&#x02009;&#x000b1;&#x02009;3.2</td><td>&#x02013;8.1&#x02009;&#x000b1;&#x02009;4.2</td><td>
<bold>0.018</bold>
</td><td/><td/><td/></tr><tr><td>&#x02003;Condyle</td><td>&#x02013;5.5&#x02009;&#x000b1;&#x02009;3.9</td><td>&#x02013;7.7&#x02009;&#x000b1;&#x02009;4.7</td><td>
<bold>0.008</bold>
</td><td/><td/><td/></tr><tr><td>&#x02003;Plateau</td><td>&#x02013;7.6&#x02009;&#x000b1;&#x02009;4.0</td><td>&#x02013;8.6&#x02009;&#x000b1;&#x02009;4.8</td><td>0.276</td><td/><td/><td/></tr><tr><td>Synovial membrane thickness<sup>b</sup> (mm)</td><td>0.13&#x02009;&#x000b1;&#x02009;0.25</td><td>0.14&#x02009;&#x000b1;&#x02009;0.24</td><td>0.948</td><td/><td/><td/></tr><tr><td>Synovial fluid volume (ml)</td><td>&#x02013;2.6&#x02009;&#x000b1;&#x02009;14.5</td><td>&#x02013;2.0&#x02009;&#x000b1;&#x02009;11.8</td><td>0.776</td><td/><td/><td/></tr><tr><td>BML score<sup>b</sup>
</td><td>1.1&#x02009;&#x000b1;&#x02009;1.7</td><td>0.8&#x02009;&#x000b1;&#x02009;1.7</td><td>0.322</td><td/><td/><td/></tr><tr><td rowspan="3">ATP population</td><td colspan="3">12&#x000a0;months</td><td colspan="3">24&#x000a0;months</td></tr><tr><td>Chondroitin sulfate</td><td>Celecoxib</td><td rowspan="2">
<italic>p</italic> value<sup>a</sup>
</td><td>Chondroitin sulfate</td><td>Celecoxib</td><td rowspan="2">
<italic>p</italic> value<sup>a</sup>
</td></tr><tr><td>(<italic>n</italic>&#x02009;=&#x02009;57)<sup>c</sup>
</td><td>(<italic>n</italic>&#x02009;=&#x02009;63)</td><td>(<italic>n</italic>&#x02009;=&#x02009;57)<sup>c</sup>
</td><td>(<italic>n</italic>&#x02009;=&#x02009;63)</td></tr><tr><td colspan="7">Cartilage volume loss (%)</td></tr><tr><td>&#x02003;Lateral compartment</td><td>&#x02013;3.4&#x02009;&#x000b1;&#x02009;2.7</td><td>&#x02013;3.3&#x02009;&#x000b1;&#x02009;2.5</td><td>0.932</td><td>&#x02013;4.6&#x02009;&#x000b1;&#x02009;3.0</td><td>&#x02013;4.4&#x02009;&#x000b1;&#x02009;2.8</td><td>0.753</td></tr><tr><td>&#x02003;&#x02003;Condyle</td><td>&#x02013;2.5&#x02009;&#x000b1;&#x02009;3.2</td><td>&#x02013;3.0&#x02009;&#x000b1;&#x02009;3.0</td><td>0.234</td><td>&#x02013;3.4&#x02009;&#x000b1;&#x02009;3.0</td><td>&#x02013;4.2&#x02009;&#x000b1;&#x02009;3.6</td><td>0.316</td></tr><tr><td>&#x02003;&#x02003;Plateau</td><td>&#x02013;4.6&#x02009;&#x000b1;&#x02009;3.5</td><td>&#x02013;3.8&#x02009;&#x000b1;&#x02009;3.1</td><td>0.194</td><td>&#x02013;6.3&#x02009;&#x000b1;&#x02009;4.6</td><td>&#x02013;4.8&#x02009;&#x000b1;&#x02009;3.5</td><td>0.081</td></tr><tr><td>&#x02003;Medial compartment</td><td>&#x02013;4.5&#x02009;&#x000b1;&#x02009;2.6</td><td>&#x02013;5.6&#x02009;&#x000b1;&#x02009;3.0</td><td>
<bold>0.049</bold>
</td><td>&#x02013;6.6&#x02009;&#x000b1;&#x02009;3.3</td><td>&#x02013;8.4&#x02009;&#x000b1;&#x02009;4.2</td><td>
<bold>0.021</bold>
</td></tr><tr><td>&#x02003;&#x02003;Condyle</td><td>&#x02013;3.8&#x02009;&#x000b1;&#x02009;3.2</td><td>&#x02013;5.0&#x02009;&#x000b1;&#x02009;3.8</td><td>0.100</td><td>&#x02013;5.7&#x02009;&#x000b1;&#x02009;4.0</td><td>&#x02013;8.1&#x02009;&#x000b1;&#x02009;4.7</td><td>
<bold>0.010</bold>
</td></tr><tr><td>&#x02003;&#x02003;Plateau</td><td>&#x02013;5.5&#x02009;&#x000b1;&#x02009;3.0</td><td>&#x02013;6.6&#x02009;&#x000b1;&#x02009;3.8</td><td>0.155</td><td>&#x02013;8.0&#x02009;&#x000b1;&#x02009;4.2</td><td>&#x02013;9.0&#x02009;&#x000b1;&#x02009;4.8</td><td>0.334</td></tr><tr><td>Synovial membrane thickness<sup>b</sup> (mm)</td><td>0.03&#x02009;&#x000b1;&#x02009;0.18</td><td>0.06&#x02009;&#x000b1;&#x02009;0.18</td><td>0.579</td><td>0.15&#x02009;&#x000b1;&#x02009;0.26</td><td>0.15&#x02009;&#x000b1;&#x02009;0.24</td><td>0.731</td></tr><tr><td>Synovial fluid volume (ml)</td><td>&#x02013;5.5&#x02009;&#x000b1;&#x02009;12.6</td><td>&#x02013;1.8&#x02009;&#x000b1;&#x02009;9.2</td><td>0.326</td><td>&#x02013;3.9&#x02009;&#x000b1;&#x02009;15.4</td><td>&#x02013;2.1&#x02009;&#x000b1;&#x02009;12.2</td><td>0.945</td></tr><tr><td>BML score<sup>b</sup>
</td><td>0.7&#x02009;&#x000b1;&#x02009;1.4</td><td>0.3&#x02009;&#x000b1;&#x02009;1.2</td><td>
<bold>0.051</bold>
</td><td>1.1&#x02009;&#x000b1;&#x02009;1.7</td><td>0.8&#x02009;&#x000b1;&#x02009;1.7</td><td>0.322</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x02009;&#x000b1;&#x02009;standard deviation</p><p>
<sup>a</sup>Analysis of covariance; model includes BMI as covariate; bold indicates statistical significance</p><p>
<sup>b</sup>Global knee</p><p>
<sup>c</sup>Among the 58 patients in the chondroitin sulfate group who completed the study, one patient did not complete the MRI at 24&#x000a0;months</p><p>
<italic>ATP</italic> according-to-protocol, <italic>BMI</italic> body mass index, <italic>BML</italic> bone marrow lesion, <italic>LOCF</italic> last observation carried forward, <italic>mITT</italic> modified intention-to-treat, <italic>MRI</italic> magnetic resonance imaging</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec13"><title>Synovial membrane</title><p>The assessment of the mean synovial thickness in the global knee (four ROIs together) was not different between treatment groups at baseline (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The change in synovial membrane thickness between the two therapeutic groups was not different at any time point in both mITT (<italic>n</italic>&#x02009;=&#x02009;138) and ATP (<italic>n</italic>&#x02009;=&#x02009;120) population analyses (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). However, in post-hoc analysis, we also examined the changes in synovial thickness in one of the four ROIs, the medial suprapatellar bursa (<italic>n</italic>&#x02009;=&#x02009;50; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Because such measurement is reliant on the presence of synovial fluid to localise the membrane, the absence of synovial fluid accounts for missing values. Data showed, in patients for whom the assessment of thickness was possible at baseline and at 24&#x000a0;months, a numerical trend (<italic>p</italic>&#x02009;=&#x02009;0.076) towards a decrease at 24&#x000a0;months in the CS group versus the celecoxib group. This is associated with a significant decrease (<italic>p</italic>&#x02009;=&#x02009;0.045) in the cartilage volume loss in the medial compartment. Moreover, when analysed based on whether patients had experienced a decrease or increase in synovial membrane thickness from baseline to 24&#x000a0;months (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), data showed that patients treated with CS had a significantly lesser increase (<italic>p</italic>&#x02009;=&#x02009;0.030) in synovial membrane thickness compared with those in the celecoxib group. The patients in the CS group who experienced a decrease in synovial membrane thickness had significantly less cartilage volume loss (<italic>p</italic>&#x02009;=&#x02009;0.036) than those in the celecoxib group.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Changes at 24&#x000a0;months in synovial membrane thickness and cartilage volume</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3"/><th colspan="3">Decrease<sup>a</sup>
</th><th colspan="3">Increase<sup>a</sup>
</th></tr><tr><th/><th>Chondroitin sulfate<break/>(<italic>n</italic>&#x02009;=&#x02009;26)<sup>b</sup>
</th><th>Celecoxib<break/>(<italic>n</italic>&#x02009;=&#x02009;24)<sup>b</sup>
</th><th>
<italic>p</italic> value<sup>c</sup>
</th><th>Chondroitin sulfate<break/>(<italic>n</italic>&#x02009;=&#x02009;12)</th><th>Celecoxib<break/>(<italic>n</italic>&#x02009;=&#x02009;8)</th><th>
<italic>p</italic> value<sup>c</sup>
</th><th>Chondroitin sulfate<break/>(<italic>n</italic>&#x02009;=&#x02009;12)</th><th>Celecoxib<break/>(<italic>n</italic>&#x02009;=&#x02009;14)</th><th>
<italic>p</italic> value<sup>c</sup>
</th></tr></thead><tbody><tr><td colspan="10">Medial suprapatellar bursa</td></tr><tr><td>&#x02003;Synovial membrane thickness loss (mm)</td><td>&#x02013;0.66&#x02009;&#x000b1;&#x02009;22.72</td><td>+17.96&#x02009;&#x000b1;&#x02009;33.73</td><td>0.076</td><td>&#x02013;0.23&#x02009;&#x000b1;&#x02009;0.27</td><td>&#x02013;0.14&#x02009;&#x000b1;&#x02009;0.21</td><td>0.446</td><td>+0.13&#x02009;&#x000b1;&#x02009;0.09</td><td>+0.25&#x02009;&#x000b1;&#x02009;0.17</td><td>
<bold>0.030</bold>
</td></tr><tr><td colspan="10">Medial compartment</td></tr><tr><td>&#x02003;Cartilage volume loss (%)</td><td>&#x02013;6.8&#x02009;&#x000b1;&#x02009;3.5</td><td>&#x02013;9.4&#x02009;&#x000b1;&#x02009;4.7</td><td>
<bold>0.045</bold>
</td><td>&#x02013;7.5&#x02009;&#x000b1;&#x02009;3.7</td><td>&#x02013;11.3&#x02009;&#x000b1;&#x02009;3.5</td><td>
<bold>0.036</bold>
</td><td>&#x02013;6.4&#x02009;&#x000b1;&#x02009;3.4</td><td>&#x02013;7.8&#x02009;&#x000b1;&#x02009;4.8</td><td>0.404</td></tr></tbody></table><table-wrap-foot><p>Data are mean&#x02009;&#x000b1;&#x02009;standard deviation</p><p>
<sup>a</sup>Data from patients who presented a decrease or an increase in synovial membrane thickness at 24&#x000a0;months</p><p>
<sup>b</sup>Synovial membrane thickness measurement is reliant on the presence of synovial fluid to localise the membrane; absence of synovial fluid accounts for missing values</p><p>
<sup>c</sup>Student&#x02019;s <italic>t</italic> test or Wilcoxon Mann&#x02013;Whitney test, bold indicates statistical significance</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>Synovial fluid volume and BML score</title><p>Analyses showed no significant differences between the two treatment groups in baseline values (randomised patients, <italic>n</italic>&#x02009;=&#x02009;194; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) or in the changes (mITT, <italic>n</italic>&#x02009;=&#x02009;138; ATP, <italic>n</italic>&#x02009;=&#x02009;120; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) in synovial fluid volume. For BML, the only significance was found in the changes at 12&#x000a0;months (<italic>p</italic>&#x02009;=&#x02009;0.051) in the ATP population.</p></sec><sec id="Sec15"><title>Joint effusion/swelling</title><p>The incidence of joint effusion and/or swelling decreased similarly in both groups during the study in the randomised patient population (all available data, baseline, <italic>n</italic>&#x02009;=&#x02009;194; Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1). A marked reduction in the incidence (%) of patients with joint swelling plus effusion was observed in both CS and celecoxib groups (42&#x000a0;% and 29&#x000a0;%, respectively) at 24&#x000a0;months.</p></sec><sec id="Sec16"><title>Symptoms and function</title><p>Both therapeutic groups experienced a reduction in disease symptoms over time (all available data; baseline <italic>n</italic>&#x02009;=&#x02009;194) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The decrease in WOMAC scores (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a&#x02013;d</xref>) was slightly more pronounced in the celecoxib group compared with the CS group, mostly at earlier time points (months 3 and 6), but statistical significance was never reached except for the WOMAC total at month 3 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>) and stiffness at months 3 and 6 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2c</xref>). At 24&#x000a0;months, the reduction in WOMAC pain (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>) was 36&#x000a0;% for the CS group and 42&#x000a0;% for the celecoxib group. The level of pain on VAS decreased over time in both treatment groups (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>). The reduction at 24&#x000a0;months was 38&#x000a0;% and 43&#x000a0;% for the CS and celecoxib groups, respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2e</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Change in symptoms and function from baseline based on available data. WOMAC (<bold>a</bold>) total, (<bold>b</bold>) pain, (<bold>c</bold>) stiffness, and (<bold>d</bold>) function subscales, and (<bold>e</bold>) VAS, by visit. Data are mean of the relative change (%) from baseline. Statistical analyses comparing chondroitin sulfate and celecoxib were performed using Student&#x02019;s <italic>t</italic> test or the Kruskal&#x02013;Wallis test. <italic>CS</italic> chondroitin sulfate, <italic>CX</italic> celecoxib, <italic>WOMAC</italic>, Western Ontario and McMaster Universities Osteoarthritis Index, <italic>VAS</italic> visual analogue scale</p></caption><graphic xlink:href="13075_2016_1149_Fig2_HTML" id="MO2"/></fig>
</p><p>With regards to the QoL SF-36 physical and mental component scores, an improvement in QoL was found for both groups without significant differences between them (data not shown).</p><p>The overall daily consumption of rescue analgesic (acetaminophen) was not different between the CS and celecoxib groups (584 versus 472&#x000a0;mg/day).</p></sec></sec><sec id="Sec17"><title>Safety</title><p>Study durations (mean&#x02009;&#x000b1;&#x02009;SD) were 581&#x02009;&#x000b1;&#x02009;254 and 579&#x02009;&#x000b1;&#x02009;262&#x000a0;days in the CS and celecoxib groups, respectively (<italic>n</italic>&#x02009;=&#x02009;194), and treatment durations were 543&#x02009;&#x000b1;&#x02009;260 and 564&#x02009;&#x000b1;&#x02009;263&#x000a0;days, respectively.</p><p>A total of 78 patients (80.4&#x000a0;%) in the CS group and 79 patients (81.4&#x000a0;%) in the celecoxib group reported at least one AE during the study. The most frequent AEs (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) at the system organ class (SOC) level were musculoskeletal and connective tissue disorders, infections and infestations, and gastrointestinal disorders. The most common AEs by preferred term were nasopharyngitis, arthralgia, dyspepsia, headache, and back pain. Significant differences between the two groups were seen only for back pain and skin and subcutaneous tissue disorders (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The vascular disorders described in the table were hypertension (CS, <italic>n</italic>&#x02009;=&#x02009;4; celecoxib, <italic>n</italic>&#x02009;=&#x02009;3) and hot flush (CS, <italic>n</italic>&#x02009;=&#x02009;1). Most emergent AEs were mild to moderate with no significant difference between treatment groups (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). The overall frequency of patients with emergent AEs considered possibly or probably related to study treatment, including cardiovascular events (mainly hypertension; CS, <italic>n</italic>&#x02009;=&#x02009;4, celecoxib, <italic>n</italic>&#x02009;=&#x02009;4), was similar in the two groups. Findings regarding the AEs leading to study withdrawal were also similar in the two therapeutic groups. No death occurred during the study. Ten patients in the CS group versus six in the celecoxib group experienced at least one serious adverse event (SAE). One SAE (iron-deficiency anaemia) was considered by the investigator to be related to treatment in one patient in the CS group and two SAEs (pneumonia and pulmonary embolism) in one patient in the celecoxib group.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Frequency of patients with at least one emergent adverse event (occurring in &#x02265;5&#x000a0;% of patients): safety population</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Chondroitin sulfate<break/>(<italic>n</italic>&#x02009;=&#x02009;97)</th><th colspan="2">Celecoxib<break/>(<italic>n</italic>&#x02009;=&#x02009;97)</th><th rowspan="2">
<italic>p</italic> value<sup>a</sup>
</th></tr><tr><th>Events</th><th>
<italic>n</italic> (%)</th><th>Events</th><th>
<italic>n</italic> (%)</th></tr></thead><tbody><tr><td>Musculoskeletal and connective tissue disorders</td><td>72</td><td>37 (38.1)</td><td>59</td><td>38 (39.2)</td><td>&#x0003e;0.999</td></tr><tr><td>&#x02003;Arthralgia</td><td>19</td><td>14 (14.4)</td><td>14</td><td>11 (11.3)</td><td>0.669</td></tr><tr><td>&#x02003;Back pain</td><td>17</td><td>16 (16.5)</td><td>5</td><td>5 (5.2)</td><td>
<bold>0.019</bold>
</td></tr><tr><td>&#x02003;Pain in extremity</td><td>6</td><td>3 (3.1)</td><td>8</td><td>7 (7.2)</td><td>0.331</td></tr><tr><td>Infections and infestations</td><td>66</td><td>34 (35.1)</td><td>61</td><td>32 (33.0)</td><td>0.880</td></tr><tr><td>&#x02003;Nasopharyngitis</td><td>28</td><td>19 (19.6)</td><td>18</td><td>15 (15.5)</td><td>0.572</td></tr><tr><td>Gastrointestinal disorders</td><td>37</td><td>27 (27.8)</td><td>44</td><td>29 (29.9)</td><td>0.874</td></tr><tr><td>&#x02003;Dyspepsia</td><td>12</td><td>12 (12.4)</td><td>12</td><td>12 (12.4)</td><td>1.000</td></tr><tr><td>&#x02003;Gastroesophageal reflux disease</td><td>5</td><td>5 (5.2)</td><td>5</td><td>5 (5.2)</td><td>1.000</td></tr><tr><td>Nervous system disorders</td><td>21</td><td>16 (16.5)</td><td>22</td><td>21 (21.6)</td><td>0.465</td></tr><tr><td>&#x02003;Headache</td><td>15</td><td>12 (12.4)</td><td>10</td><td>10 (10.3)</td><td>0.821</td></tr><tr><td>Respiratory, thoracic, and mediastinal disorders</td><td>19</td><td>15 (15.5)</td><td>20</td><td>14 (14.4)</td><td>&#x0003e;0.999</td></tr><tr><td>&#x02003;Sinusitis</td><td>5</td><td>5 (5.2)</td><td>6</td><td>6 (6.2)</td><td>&#x0003e;0.999</td></tr><tr><td>Injury, poisoning, and procedural complications</td><td>18</td><td>14 (14.4)</td><td>18</td><td>13 (13.4)</td><td>&#x0003e;0.999</td></tr><tr><td>General disorders and administration site conditions</td><td>12</td><td>11 (11.3)</td><td>12</td><td>11 (11.3)</td><td>1.000</td></tr><tr><td>Skin and subcutaneous tissue disorders</td><td>3</td><td>3 (3.1)</td><td>11</td><td>11 (11.3)</td><td>
<bold>0.049</bold>
</td></tr><tr><td>Psychiatric disorders</td><td>4</td><td>4 (4.1)</td><td>9</td><td>9 (9.3)</td><td>0.250</td></tr><tr><td>Investigations</td><td>6</td><td>6 (6.2)</td><td>6</td><td>6 (6.2)</td><td>1.000</td></tr><tr><td>Surgical and medical procedures</td><td>8</td><td>5 (5.2)</td><td>8</td><td>6 (6.2)</td><td>&#x0003e;0.999</td></tr><tr><td>Vascular disorders<sup>b</sup>
</td><td>7</td><td>6 (6.2)</td><td>5</td><td>4 (4.1)</td><td>0.747</td></tr></tbody></table><table-wrap-foot><p>Data shown are number of events or patients (%)</p><p>
<sup>a</sup>Chi-squared test or Fisher&#x02019;s exact test for proportions (%), bold indicates statistical significance</p><p>
<sup>b</sup>Vascular disorders include mainly hypertension, varicose veins, and ulcers</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Summary of emergent adverse events: safety population</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Chondroitin sulfate<break/>(<italic>n</italic>&#x02009;=&#x02009;97)</th><th colspan="2">Celecoxib<break/>(<italic>n</italic>&#x02009;=&#x02009;97)</th><th rowspan="2">
<italic>p</italic> value<sup>a</sup>
</th></tr><tr><th>Events</th><th>
<italic>n</italic> (%)</th><th>Events</th><th>
<italic>n</italic> (%)</th></tr></thead><tbody><tr><td>At least one AE</td><td>305</td><td>78 (80.4)</td><td>299</td><td>77 (79.4)</td><td>&#x0003e;0.999</td></tr><tr><td colspan="6">Intensity</td></tr><tr><td>&#x02003;Mild</td><td>203</td><td>61 (62.9)</td><td>215</td><td>61 (62.9)</td><td>1.000</td></tr><tr><td>&#x02003;Moderate</td><td>89</td><td>47 (48.5)</td><td>68</td><td>41 (42.3)</td><td>0.471</td></tr><tr><td>&#x02003;Severe</td><td>13</td><td>9 (9.3)</td><td>16</td><td>10 (10.3)</td><td>&#x0003e;0.999</td></tr><tr><td>SAE</td><td>16</td><td>10 (10.3)</td><td>9</td><td>6 (6.2)</td><td>0.435</td></tr><tr><td colspan="6">Relationship to study treatment</td></tr><tr><td>&#x02003;Not related</td><td>246</td><td>67 (69.1)</td><td>241</td><td>68 (70.1)</td><td>&#x0003e;0.999</td></tr><tr><td>&#x02003;Uncertain</td><td>20</td><td>14 (14.4)</td><td>23</td><td>13 (13.4)</td><td>&#x0003e;0.999</td></tr><tr><td>&#x02003;Related<sup>b</sup>
</td><td>39</td><td>27 (27.8)</td><td>35</td><td>24 (24.7)</td><td>0.745</td></tr><tr><td>AE that led to study withdrawal</td><td>13</td><td>13 (13.4)</td><td>12</td><td>11 (11.3)</td><td>0.828</td></tr><tr><td>Ongoing<sup>c</sup>
</td><td>95</td><td>50 (51.5)</td><td>100</td><td>50 (51.5)</td><td>1.000</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Chi-squared test for proportions (%)</p><p>
<sup>b</sup>Relationship considered possible, probable, or very probable</p><p>
<sup>c</sup>Not resolved/recovered at the end of the study</p><p>
<italic>AE</italic> adverse event, <italic>SAE</italic> severe adverse event</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec18"><title>Discussion</title><p>In this 24-month RCT, although we found no statistically significant reduction in cartilage volume loss by CS treatment in the lateral compartment, which was the primary outcome of the study, CS at 1200&#x000a0;mg/day was found to have a beneficial effect versus celecoxib 200&#x000a0;mg/day on cartilage volume loss in the medial compartment in knee OA patients. Moreover, CS, to a greater extent than celecoxib, induced a lesser increase in synovial thickness in the medial suprapatellar bursa that was associated with a decrease in cartilage volume loss in the medial compartment. There was also no evidence of superiority of one treatment over the other at improving disease symptoms except joint stiffness in the early phase of the study, which was greater in celecoxib patients. These findings provide new information about the potential benefit of long-term treatment with CS in knee OA patients.</p><p>The reduction in cartilage volume loss found with CS in the current study is in line with several other RCTs [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>] and meta-analyses and reviews [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>], in which MRI (cartilage volume) or X-ray imaging (JSN) were used to assess disease progression, a number of which used a placebo as a comparator [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>], including a pilot study using MRI [<xref ref-type="bibr" rid="CR16">16</xref>]. Of note, the results of a recent study in knee OA patients [<xref ref-type="bibr" rid="CR39">39</xref>] reported a significant reduction in cartilage volume loss with CS plus glucosamine, but not with CS alone, compared with patients treated with placebo. The results of the latter [<xref ref-type="bibr" rid="CR39">39</xref>], which used X-ray imaging and JSN to assess the disease-modifying osteoarthritis drug (DMOAD) effect, could possibly be explained by the fact that it was underpowered and of too short a duration for such imaging technology to allow an accurate assessment of possible changes related to treatment. Some other meta-analyses [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>] have reported no beneficial effect of CS on JSN. Such findings can be at least partly explained by the heterogeneity between results of the studies included in the analyses, which may have been related, to some extent, to the use of non-pharmaceutical-grade CS as the therapeutic agent in some trials [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p>The change in cartilage volume in the lateral compartment was chosen as the primary endpoint based mainly on the results of the pilot study which reported significantly less cartilage volume loss in the lateral compartment with CS versus placebo [<xref ref-type="bibr" rid="CR16">16</xref>], as well as two other knee OA RCTs using MRI [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Here, the protective effect was found only in the medial compartment. This discrepancy could probably be explained by many factors including the difference in disease severity between the patients in each study. Patients in the current study had less severe disease than those in the pilot study [<xref ref-type="bibr" rid="CR16">16</xref>], as evidenced by higher knee cartilage volume, particularly in the medial compartment. Because knee OA structural damage (cartilage volume loss) in such patients is predominantly seen in the medial compartment, disease progression in the lateral compartment may not have been sufficient for CS to demonstrate a significant therapeutic effect, as shown in a recent report [<xref ref-type="bibr" rid="CR45">45</xref>]. Moreover, the duration of treatment in the pilot study of only 12&#x000a0;months and a lower dosage of CS (800&#x000a0;mg/day) may have precluded the finding of a positive effect in the medial compartment. Nevertheless, we believe that the present findings are of great importance from many aspects. First, they are very clinically relevant, as a recent consensus of experts recommends cartilage volume loss in the medial compartment as a clinical trial outcome [<xref ref-type="bibr" rid="CR46">46</xref>]. The experts agree that it can predict knee replacement, is sensitive to change, and predicts outcome in a continuous manner. This is quite interesting in the context of the present study, because CS treatment was reported previously to have a beneficial effect on the need for total knee replacement in a 4-year follow-up study in knee OA [<xref ref-type="bibr" rid="CR47">47</xref>]. A significant number of the patients (<italic>n</italic>&#x02009;=&#x02009;134) who were randomised in the study are now being followed for a period of 4&#x000a0;years after study completion to evaluate the cumulative incidence of total knee replacement to ascertain whether the finding of our previous study [<xref ref-type="bibr" rid="CR47">47</xref>] of the sparing effect of CS treatment on knee replacement could be confirmed. The results of the present study are also most helpful with regard to the selection of primary endpoints in future DMOAD RCTs. The selection of a very specific region of the knee in OA trials may not be the most optimal approach, as demonstrated in this study and in another recent RCT report [<xref ref-type="bibr" rid="CR26">26</xref>]. This obviously needs to be examined more closely as results from additional RCTs become available.</p><p>The finding of a reduction in synovitis in the medial compartment by CS treatment in certain patients is interesting. It provides a hypothesis about the mechanism by which the effect of CS on cartilage volume loss is mediated. It also supports the findings of the pilot study regarding the effect of CS on synovitis [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>The finding that CS had a beneficial effect comparable with that of celecoxib on pain, stiffness, physical function, and QoL is in line with a recent randomised trial in which CS in combination with glucosamine provided non-inferior pain relief to celecoxib [<xref ref-type="bibr" rid="CR10">10</xref>] and supports findings from previous trials [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR48">48</xref>] and meta-analyses [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] that have also reported a significant beneficial effect of CS (with or without glucosamine) on pain. Of note is that not all clinical studies with CS have shown a significant effect on pain [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], while others found a significant effect only in patients with moderate to severe pain [<xref ref-type="bibr" rid="CR9">9</xref>]. Differences among the patient populations, product formulations that were studied, and follow-up times between studies may explain, to some extent, those discrepancies.</p><p>Regarding safety, this study confirmed the good tolerability of both treatments for up to 24&#x000a0;months, with no new safety issue, including cardiovascular events, arising for either treatment. These findings are similar to those observed in the MOVES study [<xref ref-type="bibr" rid="CR10">10</xref>], which compared the symptomatic efficacy of CS plus glucosamine hydrochloride versus celecoxib in knee OA patients. It should, however, be taken into consideration that the patients included in this study and in the MOVES study [<xref ref-type="bibr" rid="CR10">10</xref>] were those with low-risk cardiovascular and gastrointestinal diseases, which could have impacted the safety results.</p><p>As with all studies, the present study has some limitations. The relatively small sample size of this exploratory study and less severe disease severity in the patient population may have contributed to an underestimation of the effects of CS in the lateral compartment. Although patients with knee malalignment were excluded, such angulation was not assessed per se as an outcome variable and may be associated with the knee compartment in which cartilage volume loss could progress despite therapy. Additionally, although there is a well-known placebo effect in OA [<xref ref-type="bibr" rid="CR50">50</xref>], we did not include a placebo group because it was felt that this would have been unethical, particularly in a 24-month study, and CS has already been shown to have a beneficial effect on JSN and/or pain in a number of placebo-controlled studies in knee OA [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Similarly, celecoxib has proven pain efficacy over placebo in OA in several studies [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>]. Moreover, celecoxib was found to have a neutral effect similar to placebo on cartilage volume loss in knee OA patients [<xref ref-type="bibr" rid="CR16">16</xref>]. The interruption period for acetaminophen before evaluations was sufficient to have no effect on the studied pain outcomes.</p></sec><sec id="Sec19"><title>Conclusion</title><p>This trial demonstrated, for the first time in a 24-month RCT using MRI, the superiority of CS over celecoxib at reducing the long-term progression of knee OA cartilage volume loss. Moreover, both drugs were found effective at reducing the symptoms of OA over the entire duration of the 24-month study, with no superiority of one over the other. These findings are interesting with regard to the potential usefulness of CS for long-term management of knee OA. A definitive study, however, will be required if one wishes to fully confirm the findings.</p></sec></body><back><app-group><app id="App1"><sec id="Sec20"><title>Additional file</title><p>
<media position="anchor" xlink:href="13075_2016_1149_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>Includes methods (prior and concomitant treatment, blinding, treatment compliance, study schedule), <bold>Table S1.</bold> presenting inclusion and exclusion criteria, <bold>Table S2.</bold> presenting previous or concomitant medications, and <bold>Figure S1.</bold> showing joint effusion and swelling. (DOCX 60 kb)</p></caption></media>
</p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>ACR</term><def><p>American College of Rheumatology</p></def></def-item><def-item><term>AE</term><def><p>Adverse event</p></def></def-item><def-item><term>ANCOVA</term><def><p>Analysis of covariance</p></def></def-item><def-item><term>ATP</term><def><p>According-to-protocol</p></def></def-item><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>BML</term><def><p>Bone marrow lesion</p></def></def-item><def-item><term>DMOAD</term><def><p>Disease-modifying osteoarthritis drug</p></def></def-item><def-item><term>CS</term><def><p>Chondroitin sulfate</p></def></def-item><def-item><term>CV%</term><def><p>Coefficient of variation percentage</p></def></def-item><def-item><term>JSN</term><def><p>Joint space narrowing</p></def></def-item><def-item><term>LOCF</term><def><p>Last observation carried forward</p></def></def-item><def-item><term>mITT</term><def><p>Modified intention-to-treat</p></def></def-item><def-item><term>MRI</term><def><p>Magnetic resonance imaging</p></def></def-item><def-item><term>NSAID</term><def><p>Non-steroidal anti-inflammatory drug</p></def></def-item><def-item><term>OA</term><def><p>Osteoarthritis</p></def></def-item><def-item><term>qMRI</term><def><p>Quantitative magnetic resonance imaging</p></def></def-item><def-item><term>QoL</term><def><p>Quality of life</p></def></def-item><def-item><term>RCT</term><def><p>Randomised controlled trial</p></def></def-item><def-item><term>RMS</term><def><p>Root mean square</p></def></def-item><def-item><term>ROI</term><def><p>Region of interest</p></def></def-item><def-item><term>SAE</term><def><p>Serious adverse event</p></def></def-item><def-item><term>SD</term><def><p>Standard deviation</p></def></def-item><def-item><term>SYSADOA</term><def><p>Symptomatic slow-acting drug for osteoarthritis</p></def></def-item><def-item><term>VAS</term><def><p>Visual analogue scale</p></def></def-item><def-item><term>WOMAC</term><def><p>Western Ontario and McMaster Universities Osteoarthritis Index</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>Jenny Lloyd and Sophie Rushton-Smith (MedLink Healthcare Communications Ltd) provided medical writing support. The authors thank Andr&#x000e9; Pelletier and Jos&#x000e9;e Th&#x000e9;riault for the MRI reading, and Marie-Jos&#x000e9;e Berthiaume, MD, and Thomas Moser, MD, expert musculoskeletal radiologists at the University of Montreal, for the training and supervision in the MRI reading. Virginia Wallis assisted with manuscript preparation.</p><sec id="FPar1"><title>Funding</title><p>This trial was funded by Bioib&#x000e9;rica SA, Barcelona, Spain. The sponsor provided all of the study medication free of charge and met the expenses that arose during the course of the study. The sponsor also participated in the study design and data analysis (safety only).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>J-PP conceived the study, was responsible for the data collection and analysis, interpreted the data, undertook the literature search, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. J-PR conceived the study, was responsible for the data collection and analysis, interpreted the data, undertook the literature search, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. ADB was responsible for the data collection and analysis, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. LB was responsible for the data collection and analysis, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. FM was responsible for the data collection and analysis, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. AJdB-F was responsible for the data collection and analysis, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. PD was responsible for the data collection and analysis, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. MD was responsible for the data collection and analysis, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. PP was responsible for the data collection and analysis, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. FA was responsible for the data collection and analysis, interpreted the data, undertook the literature search, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version. JM-P conceived the study, was responsible for the data collection and analysis, interpreted the data, undertook the literature search, was involved in the drafting or critical revision of the manuscript, and approved the final submitted version.</p></sec><sec id="FPar5"><title>Authors&#x02019; information</title><p>Not applicable.</p></sec><sec id="FPar4"><title>Competing interests</title><p>J-PP is a shareholder in ArthroLab and consultant for Bioib&#x000e9;rica. J-PR is a consultant for ArthroLab. MD is a consultant for ArthroLab. PD, PP, and FA are employees of ArthroLab. JM-P is a shareholder in ArthroLab and consultant for Bioib&#x000e9;rica. No non-financial conflicts of interest exist for any of the authors.</p></sec><sec id="FPar6"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar7"><title>Ethics approval and consent to participate</title><p>The study protocol was approved by a central review board (IRB Institutional Review Board Services, Toronto, ON, Canada) and the institutional review board of the Centre hospitalier de l&#x02019;Universit&#x000e9; de Sherbrooke (CHUS), Sherbrooke, QC, Canada. The trial was conducted in compliance with the ethical principles that have their origin in the Declaration of Helsinki (2000) and are consistent with the &#x0201c;Good Clinical Practice&#x0201d; ICH Tripartite Guideline (January 1997) and the applicable laws and regulations of Canada, whichever afforded the greater protection to the individual. All patients provided informed consent.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Flaxman</surname><given-names>AD</given-names></name><name><surname>Michaud</surname><given-names>C</given-names></name><name><surname>Ezzati</surname><given-names>M</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Salomon</surname><given-names>JA</given-names></name><name><surname>Abdalla</surname><given-names>S</given-names></name><etal/></person-group><article-title>Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><issue>9859</issue><fpage>2197</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61689-4</pub-id><pub-id pub-id-type="pmid">23245608</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woolf</surname><given-names>AD</given-names></name><name><surname>Pfleger</surname><given-names>B</given-names></name></person-group><article-title>Burden of major musculoskeletal conditions</article-title><source>Bull World Health Organ</source><year>2003</year><volume>81</volume><issue>9</issue><fpage>646</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">14710506</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruyere</surname><given-names>O</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Branco</surname><given-names>J</given-names></name><name><surname>Luisa Brandi</surname><given-names>M</given-names></name><name><surname>Guillemin</surname><given-names>F</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>Kvien</surname><given-names>TK</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><etal/></person-group><article-title>An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)</article-title><source>Semin Arthritis Rheum</source><year>2014</year><volume>44</volume><issue>3</issue><fpage>253</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2014.05.014</pub-id><pub-id pub-id-type="pmid">24953861</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>D</given-names></name><name><surname>Bejarano</surname><given-names>T</given-names></name><name><surname>Novo</surname><given-names>M</given-names></name></person-group><article-title>Current interventions in the management of knee osteoarthritis</article-title><source>J Pharm Bioallied Sci</source><year>2013</year><volume>5</volume><issue>1</issue><fpage>30</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4103/0975-7406.106561</pub-id><pub-id pub-id-type="pmid">23559821</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>KM</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Bannwarth</surname><given-names>B</given-names></name><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Dieppe</surname><given-names>P</given-names></name><name><surname>Gunther</surname><given-names>K</given-names></name><name><surname>Hauselmann</surname><given-names>H</given-names></name><name><surname>Herrero-Beaumont</surname><given-names>G</given-names></name><name><surname>Kaklamanis</surname><given-names>P</given-names></name><etal/></person-group><article-title>EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)</article-title><source>Ann Rheum Dis</source><year>2003</year><volume>62</volume><issue>12</issue><fpage>1145</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1136/ard.2003.011742</pub-id><pub-id pub-id-type="pmid">14644851</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Altman</surname><given-names>RD</given-names></name><name><surname>April</surname><given-names>KT</given-names></name><name><surname>Benkhalti</surname><given-names>M</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>McGowan</surname><given-names>J</given-names></name><name><surname>Towheed</surname><given-names>T</given-names></name><name><surname>Welch</surname><given-names>V</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name><name><surname>Tugwell</surname><given-names>P</given-names></name></person-group><article-title>American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee</article-title><source>Arthritis Care Res (Hoboken)</source><year>2012</year><volume>64</volume><issue>4</issue><fpage>465</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1002/acr.21596</pub-id><pub-id pub-id-type="pmid">22563589</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAlindon</surname><given-names>TE</given-names></name><name><surname>Bannuru</surname><given-names>RR</given-names></name><name><surname>Sullivan</surname><given-names>MC</given-names></name><name><surname>Arden</surname><given-names>NK</given-names></name><name><surname>Berenbaum</surname><given-names>F</given-names></name><name><surname>Bierma-Zeinstra</surname><given-names>SM</given-names></name><name><surname>Hawker</surname><given-names>GA</given-names></name><name><surname>Henrotin</surname><given-names>Y</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Kawaguchi</surname><given-names>H</given-names></name><etal/></person-group><article-title>OARSI guidelines for the non-surgical management of knee osteoarthritis</article-title><source>Osteoarthritis Cartilage</source><year>2014</year><volume>22</volume><issue>3</issue><fpage>363</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2014.01.003</pub-id><pub-id pub-id-type="pmid">24462672</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>E</given-names></name><name><surname>Delgado Nunes</surname><given-names>V</given-names></name><name><surname>Buckner</surname><given-names>S</given-names></name><name><surname>Latchem</surname><given-names>S</given-names></name><name><surname>Constanti</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>P</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Birrell</surname><given-names>F</given-names></name><name><surname>Porcheret</surname><given-names>M</given-names></name><etal/></person-group><article-title>Paracetamol: not as safe as we thought? A systematic literature review of observational studies</article-title><source>Ann Rheum Dis</source><year>2016</year><volume>75</volume><issue>3</issue><fpage>552</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2014-206914</pub-id><pub-id pub-id-type="pmid">25732175</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clegg</surname><given-names>DO</given-names></name><name><surname>Reda</surname><given-names>DJ</given-names></name><name><surname>Harris</surname><given-names>CL</given-names></name><name><surname>Klein</surname><given-names>MA</given-names></name><name><surname>O'Dell</surname><given-names>JR</given-names></name><name><surname>Hooper</surname><given-names>MM</given-names></name><name><surname>Bradley</surname><given-names>JD</given-names></name><name><surname>Bingham</surname><given-names>CO</given-names></name><name><surname>Weisman</surname><given-names>MH</given-names></name><name><surname>Jackson</surname><given-names>CG</given-names></name><etal/></person-group><article-title>Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><issue>8</issue><fpage>795</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa052771</pub-id><pub-id pub-id-type="pmid">16495392</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Monfort</surname><given-names>J</given-names></name><name><surname>Moller</surname><given-names>I</given-names></name><name><surname>Castillo</surname><given-names>JR</given-names></name><name><surname>Arden</surname><given-names>N</given-names></name><name><surname>Berenbaum</surname><given-names>F</given-names></name><name><surname>Blanco</surname><given-names>FJ</given-names></name><name><surname>Conaghan</surname><given-names>PG</given-names></name><name><surname>Domenech</surname><given-names>G</given-names></name><etal/></person-group><article-title>Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib</article-title><source>Ann Rheum Dis</source><year>2016</year><volume>75</volume><issue>1</issue><fpage>37</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2014-206792</pub-id><pub-id pub-id-type="pmid">25589511</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>JA</given-names></name><name><surname>Noorbaloochi</surname><given-names>S</given-names></name><name><surname>MacDonald</surname><given-names>R</given-names></name><name><surname>Maxwell</surname><given-names>LJ</given-names></name></person-group><article-title>Chondroitin for osteoarthritis</article-title><source>Cochrane Database Syst Rev</source><year>2015</year><volume>1</volume><pub-id pub-id-type="pmid">25629804</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Farran</surname><given-names>A</given-names></name><name><surname>Montell</surname><given-names>E</given-names></name><name><surname>Verges</surname><given-names>J</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>Discrepancies in composition and biological effects of different formulations of chondroitin sulfate</article-title><source>Molecules</source><year>2015</year><volume>20</volume><issue>3</issue><fpage>4277</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.3390/molecules20034277</pub-id><pub-id pub-id-type="pmid">25756648</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahan</surname><given-names>A</given-names></name><name><surname>Uebelhart</surname><given-names>D</given-names></name><name><surname>De Vathaire</surname><given-names>F</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name></person-group><article-title>Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial</article-title><source>Arthritis Rheum</source><year>2009</year><volume>60</volume><issue>2</issue><fpage>524</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1002/art.24255</pub-id><pub-id pub-id-type="pmid">19180484</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>BA</given-names></name><name><surname>Stucki</surname><given-names>G</given-names></name><name><surname>Frey</surname><given-names>D</given-names></name><name><surname>De Vathaire</surname><given-names>F</given-names></name><name><surname>Vignon</surname><given-names>E</given-names></name><name><surname>Bruehlmann</surname><given-names>P</given-names></name><name><surname>Uebelhart</surname><given-names>D</given-names></name></person-group><article-title>Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><issue>3</issue><fpage>779</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1002/art.20867</pub-id><pub-id pub-id-type="pmid">15751094</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uebelhart</surname><given-names>D</given-names></name><name><surname>Malaise</surname><given-names>M</given-names></name><name><surname>Marcolongo</surname><given-names>R</given-names></name><name><surname>DeVathaire</surname><given-names>F</given-names></name><name><surname>Piperno</surname><given-names>M</given-names></name><name><surname>Mailleux</surname><given-names>E</given-names></name><name><surname>Fioravanti</surname><given-names>A</given-names></name><name><surname>Matoso</surname><given-names>L</given-names></name><name><surname>Vignon</surname><given-names>E</given-names></name></person-group><article-title>Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one-year, randomized, double-blind, multicenter study versus placebo</article-title><source>Osteoarthritis Cartilage</source><year>2004</year><volume>12</volume><issue>4</issue><fpage>269</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2004.01.004</pub-id><pub-id pub-id-type="pmid">15023378</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildi</surname><given-names>LM</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Beaulieu</surname><given-names>A</given-names></name><name><surname>Bessette</surname><given-names>L</given-names></name><name><surname>Morin</surname><given-names>F</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6&#x000a0;months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><issue>6</issue><fpage>982</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1136/ard.2010.140848</pub-id><pub-id pub-id-type="pmid">21367761</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>PS</given-names></name><name><surname>Caron</surname><given-names>JP</given-names></name><name><surname>Orth</surname><given-names>MW</given-names></name></person-group><article-title>Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants</article-title><source>Am J Vet Res</source><year>2005</year><volume>66</volume><issue>11</issue><fpage>1870</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.2460/ajvr.2005.66.1870</pub-id><pub-id pub-id-type="pmid">16334942</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tat</surname><given-names>SK</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Verg&#x000e9;s</surname><given-names>J</given-names></name><name><surname>Montell</surname><given-names>E</given-names></name><name><surname>Lajeunesse</surname><given-names>D</given-names></name><name><surname>Fahmi</surname><given-names>H</given-names></name><name><surname>Lavigne</surname><given-names>M</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name></person-group><article-title>Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts</article-title><source>Arthritis Res Ther</source><year>2007</year><volume>9</volume><fpage>R117</fpage><pub-id pub-id-type="doi">10.1186/ar2325</pub-id><pub-id pub-id-type="pmid">17996099</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monfort</surname><given-names>J</given-names></name><name><surname>Pelletier</surname><given-names>J-P</given-names></name><name><surname>Garcia-Giralt</surname><given-names>N</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name></person-group><article-title>Biochemical basis of the effect of chondroitin sulfate on osteoarthritis articular tissues</article-title><source>Ann Rheum Dis</source><year>2008</year><volume>67</volume><fpage>735</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1136/ard.2006.068882</pub-id><pub-id pub-id-type="pmid">17644553</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>du Souich</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>AG</given-names></name><name><surname>Verges</surname><given-names>J</given-names></name><name><surname>Montell</surname><given-names>E</given-names></name></person-group><article-title>Immunomodulatory and anti-inflammatory effects of chondroitin sulphate</article-title><source>J Cell Mol Med</source><year>2009</year><volume>13</volume><issue>8A</issue><fpage>1451</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00826.x</pub-id><pub-id pub-id-type="pmid">19522843</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Kwan Tat</surname><given-names>S</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>Effects of chondroitin sulfate in the pathophysiology of the osteoarthritic joint: a narrative review</article-title><source>Osteoarthritis Cartilage</source><year>2010</year><volume>18</volume><issue>Suppl 1</issue><fpage>S7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2010.01.015</pub-id><pub-id pub-id-type="pmid">20399897</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Beaulieu</surname><given-names>A</given-names></name><name><surname>Bessette</surname><given-names>L</given-names></name><name><surname>Morin</surname><given-names>F</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis</article-title><source>Semin Arthritis Rheum</source><year>2010</year><volume>40</volume><issue>3</issue><fpage>185</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2009.10.003</pub-id><pub-id pub-id-type="pmid">20132966</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensen</surname><given-names>WG</given-names></name><name><surname>Fiechtner</surname><given-names>JJ</given-names></name><name><surname>McMillen</surname><given-names>JI</given-names></name><name><surname>Zhao</surname><given-names>WW</given-names></name><name><surname>Yu</surname><given-names>SS</given-names></name><name><surname>Woods</surname><given-names>EM</given-names></name><name><surname>Hubbard</surname><given-names>RC</given-names></name><name><surname>Isakson</surname><given-names>PC</given-names></name><name><surname>Verburg</surname><given-names>KM</given-names></name><name><surname>Geis</surname><given-names>GS</given-names></name></person-group><article-title>Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial</article-title><source>Mayo Clin Proc</source><year>1999</year><volume>74</volume><issue>11</issue><fpage>1095</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.4065/74.11.1095</pub-id><pub-id pub-id-type="pmid">10560596</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>RD</given-names></name><name><surname>Asch</surname><given-names>E</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>Bole</surname><given-names>G</given-names></name><name><surname>Borenstein</surname><given-names>D</given-names></name><name><surname>Brandt</surname><given-names>KD</given-names></name><name><surname>Christy</surname><given-names>W</given-names></name><name><surname>Cooke</surname><given-names>TD</given-names></name><name><surname>Greenwald</surname><given-names>R</given-names></name><name><surname>Hochberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee</article-title><source>Arthritis Rheum</source><year>1986</year><volume>29</volume><fpage>1039</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1002/art.1780290816</pub-id><pub-id pub-id-type="pmid">3741515</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellgren</surname><given-names>JH</given-names></name><name><surname>Lawrence</surname><given-names>JS</given-names></name></person-group><article-title>Radiological assessment of osteoarthosis</article-title><source>Ann Rheum Dis</source><year>1957</year><volume>16</volume><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1136/ard.16.4.494</pub-id><pub-id pub-id-type="pmid">13498604</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohmander</surname><given-names>LS</given-names></name><name><surname>Hellot</surname><given-names>S</given-names></name><name><surname>Dreher</surname><given-names>D</given-names></name><name><surname>Krantz</surname><given-names>EF</given-names></name><name><surname>Kruger</surname><given-names>DS</given-names></name><name><surname>Guermazi</surname><given-names>A</given-names></name><name><surname>Eckstein</surname><given-names>F</given-names></name></person-group><article-title>Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial</article-title><source>Arthritis Rheumatol</source><year>2014</year><volume>66</volume><issue>7</issue><fpage>1820</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1002/art.38614</pub-id><pub-id pub-id-type="pmid">24740822</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Bias</surname><given-names>P</given-names></name><name><surname>Laufer</surname><given-names>S</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Beaulieu</surname><given-names>AD</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Vignon</surname><given-names>E</given-names></name><etal/></person-group><article-title>Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI</article-title><source>Ann Rheum Dis</source><year>2009</year><volume>68</volume><issue>6</issue><fpage>938</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1136/ard.2008.088732</pub-id><pub-id pub-id-type="pmid">18653484</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildi</surname><given-names>LM</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Moser</surname><given-names>T</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>Assessment of cartilage changes over time in knee osteoarthritis disease-modifying osteoarthritis drug trials using semiquantitative and quantitative methods: pros and cons</article-title><source>Arthritis Care Res (Hoboken)</source><year>2013</year><volume>65</volume><issue>5</issue><fpage>686</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1002/acr.21890</pub-id><pub-id pub-id-type="pmid">23139244</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name></person-group><article-title>A new non-invasive method to assess synovitis severity in relation to symptoms and cartilage volume loss in knee osteoarthritis patients using MRI</article-title><source>Osteoarthritis Cartilage</source><year>2008</year><volume>16</volume><issue>Suppl 3</issue><fpage>S8</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2008.06.007</pub-id><pub-id pub-id-type="pmid">18672386</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Berthiaume</surname><given-names>MJ</given-names></name><name><surname>Labont&#x000e9;</surname><given-names>F</given-names></name><name><surname>Beaudoin</surname><given-names>G</given-names></name><name><surname>de Guise</surname><given-names>JA</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Altman</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>476</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1002/art.20000</pub-id><pub-id pub-id-type="pmid">14872490</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kauffmann</surname><given-names>C</given-names></name><name><surname>Gravel</surname><given-names>P</given-names></name><name><surname>Godbout</surname><given-names>B</given-names></name><name><surname>Gravel</surname><given-names>A</given-names></name><name><surname>Beaudoin</surname><given-names>G</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>de Guise</surname><given-names>JA</given-names></name></person-group><article-title>Computer-aided method for quantification of cartilage thickness and volume changes using MRI: validation study using a synthetic model</article-title><source>IEEE Trans Biomed Eng</source><year>2003</year><volume>50</volume><issue>8</issue><fpage>978</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1109/TBME.2003.814539</pub-id><pub-id pub-id-type="pmid">12892325</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Kauffmann</surname><given-names>C</given-names></name><name><surname>Beaudoin</surname><given-names>G</given-names></name><name><surname>Berthiaume</surname><given-names>MJ</given-names></name><name><surname>de Guise</surname><given-names>JA</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>Camacho</surname><given-names>F</given-names></name><name><surname>Godbout</surname><given-names>B</given-names></name><name><surname>Altman</surname><given-names>RD</given-names></name><name><surname>Hochberg</surname><given-names>M</given-names></name><etal/></person-group><article-title>Reliability of a quantification imaging system using magnetic resonance images to measure cartilage thickness and volume in human normal and osteoarthritic knees</article-title><source>Osteoarthritis Cartilage</source><year>2003</year><volume>11</volume><issue>5</issue><fpage>351</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/S1063-4584(03)00029-3</pub-id><pub-id pub-id-type="pmid">12744941</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>d'Anjou</surname><given-names>MA</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name></person-group><article-title>Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging</article-title><source>Arthritis Res Ther</source><year>2010</year><volume>12</volume><issue>5</issue><fpage>R173</fpage><pub-id pub-id-type="doi">10.1186/ar3133</pub-id><pub-id pub-id-type="pmid">20846392</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Berthiaume</surname><given-names>MJ</given-names></name><name><surname>Beaudoin</surname><given-names>G</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Tannenbaum</surname><given-names>H</given-names></name><name><surname>Meyer</surname><given-names>JM</given-names></name><name><surname>Beary</surname><given-names>JF</given-names></name><name><surname>Cline</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes</article-title><source>Arthritis Res Ther</source><year>2006</year><volume>8</volume><issue>1</issue><fpage>R21</fpage><pub-id pub-id-type="doi">10.1186/ar1875</pub-id><pub-id pub-id-type="pmid">16507119</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>B</given-names></name><name><surname>Tjoumakaris</surname><given-names>FP</given-names></name><name><surname>Harwood</surname><given-names>MI</given-names></name><name><surname>Good</surname><given-names>RP</given-names></name><name><surname>Ciccotti</surname><given-names>MG</given-names></name><name><surname>Freedman</surname><given-names>KB</given-names></name></person-group><article-title>Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents</article-title><source>Am J Sports Med</source><year>2015</year><volume>43</volume><issue>3</issue><fpage>734</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1177/0363546514533777</pub-id><pub-id pub-id-type="pmid">24866892</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>M</given-names></name><name><surname>Chevalier</surname><given-names>X</given-names></name><name><surname>Henrotin</surname><given-names>Y</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Uebelhart</surname><given-names>D</given-names></name></person-group><article-title>Symptom and structure modification in osteoarthritis with pharmaceutical-grade chondroitin sulfate: what's the evidence?</article-title><source>Curr Med Res Opin</source><year>2013</year><volume>29</volume><issue>3</issue><fpage>259</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1185/03007995.2012.753430</pub-id><pub-id pub-id-type="pmid">23186102</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group><article-title>Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration</article-title><source>Osteoarthritis Cartilage</source><year>2010</year><volume>18</volume><issue>Suppl 1</issue><fpage>S28</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2010.02.016</pub-id><pub-id pub-id-type="pmid">20399895</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Woo</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name><name><surname>Song</surname><given-names>GG</given-names></name></person-group><article-title>Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis</article-title><source>Rheumatol Int</source><year>2010</year><volume>30</volume><issue>3</issue><fpage>357</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s00296-009-0969-5</pub-id><pub-id pub-id-type="pmid">19544061</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fransen</surname><given-names>M</given-names></name><name><surname>Agaliotis</surname><given-names>M</given-names></name><name><surname>Nairn</surname><given-names>L</given-names></name><name><surname>Votrubec</surname><given-names>M</given-names></name><name><surname>Bridgett</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Jan</surname><given-names>S</given-names></name><name><surname>March</surname><given-names>L</given-names></name><name><surname>Edmonds</surname><given-names>J</given-names></name><name><surname>Norton</surname><given-names>R</given-names></name><etal/></person-group><article-title>Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens</article-title><source>Ann Rheum Dis</source><year>2015</year><volume>74</volume><issue>5</issue><fpage>851</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203954</pub-id><pub-id pub-id-type="pmid">24395557</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wandel</surname><given-names>S</given-names></name><name><surname>Juni</surname><given-names>P</given-names></name><name><surname>Tendal</surname><given-names>B</given-names></name><name><surname>Nuesch</surname><given-names>E</given-names></name><name><surname>Villiger</surname><given-names>PM</given-names></name><name><surname>Welton</surname><given-names>NJ</given-names></name><name><surname>Reichenbach</surname><given-names>S</given-names></name><name><surname>Trelle</surname><given-names>S</given-names></name></person-group><article-title>Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis</article-title><source>BMJ</source><year>2010</year><volume>341</volume><fpage>c4675</fpage><pub-id pub-id-type="doi">10.1136/bmj.c4675</pub-id><pub-id pub-id-type="pmid">20847017</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichenbach</surname><given-names>S</given-names></name><name><surname>Sterchi</surname><given-names>R</given-names></name><name><surname>Scherer</surname><given-names>M</given-names></name><name><surname>Trelle</surname><given-names>S</given-names></name><name><surname>Burgi</surname><given-names>E</given-names></name><name><surname>Burgi</surname><given-names>U</given-names></name><name><surname>Dieppe</surname><given-names>PA</given-names></name><name><surname>Juni</surname><given-names>P</given-names></name></person-group><article-title>Meta-analysis: chondroitin for osteoarthritis of the knee or hip</article-title><source>Ann Intern Med</source><year>2007</year><volume>146</volume><issue>8</issue><fpage>580</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-146-8-200704170-00009</pub-id><pub-id pub-id-type="pmid">17438317</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richy</surname><given-names>F</given-names></name><name><surname>Bruyere</surname><given-names>O</given-names></name><name><surname>Ethgen</surname><given-names>O</given-names></name><name><surname>Cucherat</surname><given-names>M</given-names></name><name><surname>Henrotin</surname><given-names>Y</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name></person-group><article-title>Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis</article-title><source>Arch Intern Med</source><year>2003</year><volume>163</volume><issue>13</issue><fpage>1514</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1001/archinte.163.13.1514</pub-id><pub-id pub-id-type="pmid">12860572</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henrotin</surname><given-names>YE</given-names></name></person-group><article-title>Interpretation of metaanalyses: pitfalls should be more widely recognized</article-title><source>J Rheumatol</source><year>2012</year><volume>39</volume><issue>6</issue><fpage>1107</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3899/jrheum.111420</pub-id><pub-id pub-id-type="pmid">22382339</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rainsford</surname><given-names>KD</given-names></name></person-group><article-title>Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique</article-title><source>J Pharm Pharmacol</source><year>2009</year><volume>61</volume><issue>10</issue><fpage>1263</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1211/jpp.61.10.0001</pub-id><pub-id pub-id-type="pmid">19814857</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roubille</surname><given-names>C</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Delorme</surname><given-names>P</given-names></name><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Pelletier</surname><given-names>JP</given-names></name></person-group><article-title>Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: data from the OAI progression cohort</article-title><source>Semin Arthritis Rheum</source><year>2015</year><volume>45</volume><issue>3</issue><fpage>257</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2015.05.001</pub-id><pub-id pub-id-type="pmid">26094904</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>JP</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Peterfy</surname><given-names>C</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name><name><surname>Brandi</surname><given-names>ML</given-names></name><name><surname>Bruyere</surname><given-names>O</given-names></name><name><surname>Chapurlat</surname><given-names>R</given-names></name><name><surname>Cicuttini</surname><given-names>F</given-names></name><name><surname>Conaghan</surname><given-names>PG</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><etal/></person-group><article-title>What is the predictive value of MRI for the occurrence of knee replacement surgery in knee osteoarthritis?</article-title><source>Ann Rheum Dis</source><year>2013</year><volume>72</volume><issue>10</issue><fpage>1594</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203631</pub-id><pub-id pub-id-type="pmid">23887285</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raynauld</surname><given-names>JP</given-names></name><name><surname>Martel-Pelletier</surname><given-names>J</given-names></name><name><surname>Dorais</surname><given-names>M</given-names></name><name><surname>Haraoui</surname><given-names>B</given-names></name><name><surname>Choquette</surname><given-names>D</given-names></name><name><surname>Abram</surname><given-names>F</given-names></name><name><surname>Beaulieu</surname><given-names>A</given-names></name><name><surname>Bessette</surname><given-names>L</given-names></name><name><surname>Morin</surname><given-names>F</given-names></name><name><surname>Wildi</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Total knee replacement as a knee osteoarthritis outcome: predictors derived from a 4&#x000a0;year long-term observation following a randomized clinical trial using chondroitin sulfate</article-title><source>Cartilage</source><year>2013</year><volume>4</volume><issue>3</issue><fpage>219</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1177/1947603513483547</pub-id><pub-id pub-id-type="pmid">26069668</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>I</given-names></name><name><surname>Perez</surname><given-names>M</given-names></name><name><surname>Monfort</surname><given-names>J</given-names></name><name><surname>Benito</surname><given-names>P</given-names></name><name><surname>Cuevas</surname><given-names>J</given-names></name><name><surname>Perna</surname><given-names>C</given-names></name><name><surname>Domenech</surname><given-names>G</given-names></name><name><surname>Herrero</surname><given-names>M</given-names></name><name><surname>Montell</surname><given-names>E</given-names></name><name><surname>Verges</surname><given-names>J</given-names></name></person-group><article-title>Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study</article-title><source>Osteoarthritis Cartilage</source><year>2010</year><volume>18</volume><issue>Suppl 1</issue><fpage>S32</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2010.01.018</pub-id><pub-id pub-id-type="pmid">20399899</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>H</given-names></name><name><surname>Maheu</surname><given-names>E</given-names></name><name><surname>Cucherat</surname><given-names>M</given-names></name></person-group><article-title>Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: a meta-analysis of randomized placebo-controlled trials performed with structum&#x000ae;</article-title><source>Open Rheumatol J</source><year>2012</year><volume>6</volume><fpage>183</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2174/1874312901206010183</pub-id><pub-id pub-id-type="pmid">22870166</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Campos</surname><given-names>GC</given-names></name></person-group><article-title>Placebo effect in osteoarthritis: Why not use it to our advantage?</article-title><source>World J Orthop</source><year>2015</year><volume>6</volume><issue>5</issue><fpage>416</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.5312/wjo.v6.i5.416</pub-id><pub-id pub-id-type="pmid">26085983</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conaghan</surname><given-names>PG</given-names></name><name><surname>Dickson</surname><given-names>J</given-names></name><name><surname>Bolten</surname><given-names>W</given-names></name><name><surname>Cevc</surname><given-names>G</given-names></name><name><surname>Rother</surname><given-names>M</given-names></name></person-group><article-title>A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis</article-title><source>Rheumatology (Oxford)</source><year>2013</year><volume>52</volume><issue>7</issue><fpage>1303</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ket133</pub-id><pub-id pub-id-type="pmid">23542612</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bingham</surname><given-names>CO</given-names><suffix>3rd</suffix></name><name><surname>Sebba</surname><given-names>AI</given-names></name><name><surname>Rubin</surname><given-names>BR</given-names></name><name><surname>Ruoff</surname><given-names>GE</given-names></name><name><surname>Kremer</surname><given-names>J</given-names></name><name><surname>Bird</surname><given-names>S</given-names></name><name><surname>Smugar</surname><given-names>SS</given-names></name><name><surname>Fitzgerald</surname><given-names>BJ</given-names></name><name><surname>O'Brien</surname><given-names>K</given-names></name><name><surname>Tershakovec</surname><given-names>AM</given-names></name></person-group><article-title>Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies</article-title><source>Rheumatology (Oxford)</source><year>2007</year><volume>46</volume><issue>3</issue><fpage>496</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kel296</pub-id><pub-id pub-id-type="pmid">16936327</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tannenbaum</surname><given-names>H</given-names></name><name><surname>Berenbaum</surname><given-names>F</given-names></name><name><surname>Reginster</surname><given-names>JY</given-names></name><name><surname>Zacher</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Poor</surname><given-names>G</given-names></name><name><surname>Bliddal</surname><given-names>H</given-names></name><name><surname>Uebelhart</surname><given-names>D</given-names></name><name><surname>Adami</surname><given-names>S</given-names></name><name><surname>Navarro</surname><given-names>F</given-names></name><etal/></person-group><article-title>Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13&#x000a0;week, randomised, double blind study versus placebo and celecoxib</article-title><source>Ann Rheum Dis</source><year>2004</year><volume>63</volume><issue>11</issue><fpage>1419</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1136/ard.2003.015974</pub-id><pub-id pub-id-type="pmid">15020310</pub-id></element-citation></ref></ref-list></back></article>